Log in

Relevant bibliographies by topics / Adenosine Deaminase; Rhubarb; Cancer / Journal articles

To see the other types of publications on this topic, follow the link: Adenosine Deaminase; Rhubarb; Cancer.

Journal articles on the topic 'Adenosine Deaminase; Rhubarb; Cancer'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Adenosine Deaminase; Rhubarb; Cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Zahide, Esra Durak, Büber Süleyman, Devrim Erdinç, Kocaoğlu Hilmi, and Durak İlker. "Aquoeus Extract from Rhubarb Plant Inhibits Adenosine Deaminase Activity in Cancerous and Non Cancerous Human Gastric and Colon Tissues." Journal of Progressive Research in Chemistry 1, no. 1 (2015): 9–13. https://doi.org/10.5281/zenodo.3970308.

Full text

Abstract:

Aim: Investigation of possible effects of rhubarb extract on adenosine deaminase (ADA) activity in cancerous and non cancerous human gastric and colon tissues to obtain information about possible mechanism of anti cancer action of rhubarb. Materials and methods: Cancerous and non cancerous human gastric and colon tissues removed from patients by surgical operations were used in the studies. The extracts were prepared in distilled water. Before and after treatment with the extracts, ADA activities in the tissue homogenates were measured. Results: ADA activity was found to be higher in gastric t

APA, Harvard, Vancouver, ISO, and other styles

2

Zhulai, Galina, Eugenia Oleinik, Mikhail Shibaev, and Kirill Ignatev. "Adenosine-Metabolizing Enzymes, Adenosine Kinase and Adenosine Deaminase, in Cancer." Biomolecules 12, no. 3 (2022): 418. http://dx.doi.org/10.3390/biom12030418.

Full text

Abstract:

The immunosuppressive effect of adenosine in the microenvironment of a tumor is well established. Presently, researchers are developing approaches in immune therapy that target inhibition of adenosine or its signaling such as CD39 or CD73 inhibiting antibodies or adenosine A2A receptor antagonists. However, numerous enzymatic pathways that control ATP-adenosine balance, as well as understudied intracellular adenosine regulation, can prevent successful immunotherapy. This review contains the latest data on two adenosine-lowering enzymes: adenosine kinase (ADK) and adenosine deaminase (ADA). ADK

APA, Harvard, Vancouver, ISO, and other styles

3

Shatova, O. P., Eu V. Butenko, Eu V. Khomutov, D. S. Kaplun, I. Eu Sedakov, and I. I. Zinkovych. "Metformin impact on purine metabolism in breast cancer." Biomeditsinskaya Khimiya 62, no. 3 (2016): 302–5. http://dx.doi.org/10.18097/pbmc20166203302.

Full text

Abstract:

Large-scale epidemiological and clinical studies have demonstrated the efficacy of metformin in oncology practice. However, the mechanisms of implementation of the anti-tumor effect of this drug there is still need understanding. In this study we have investigated the effect of metformin on the activity of adenosine deaminase and respectively adenosinergic immunosuppression in tumors and their microenvironment. The material of the study was taken during surgery of breast cacer patients receiveing metformin, and also patients which did not take this drug. The adenosine deaminase activity and su

APA, Harvard, Vancouver, ISO, and other styles

4

Namiot, Z., A. Kemona, J. Stasiewicz, M. Marcinkiewicz, A. Namiot, and J. Gorski. "Adenosine deaminase activity in gastric cancer." Cancer Letters 82, no. 1 (1994): 95–98. http://dx.doi.org/10.1016/0304-3835(94)90151-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Journal, Baghdad Science. "Chemotherapy Effects on the Activities of Some Purine Metabolic Enzymes in Sera of Ovarian Cancer Patients." Baghdad Science Journal 7, no. 3 (2010): 1166–73. http://dx.doi.org/10.21123/bsj.7.3.1166-1173.

Full text

Abstract:

Adenosine deaminase (ADA; Ec: 3.5.4.4), 5´- Nucleotidase (5´– NT; Ec: 3.1.3.5), and AMP – amino hydrolase (AMP – deaminase AMPDA; Ec: 3.5.4.6) activities were measured in sera of ovarian cancer patients before surgery, and after chemotherapy. The results indicated that ADA specific activity increased significantly (P

APA, Harvard, Vancouver, ISO, and other styles

6

Al-Shammaree, Shatha Abd AL Wadood. "Chemotherapy Effects on the Activities of Some Purine Metabolic Enzymes in Sera of Ovarian Cancer Patients." Baghdad Science Journal 7, no. 3 (2010): 1166–73. http://dx.doi.org/10.21123/bsj.2010.7.3.1166-1173.

Full text

Abstract:

Adenosine deaminase (ADA; Ec: 3.5.4.4), 5´- Nucleotidase (5´– NT; Ec: 3.1.3.5), and AMP – amino hydrolase (AMP – deaminase AMPDA; Ec: 3.5.4.6) activities were measured in sera of ovarian cancer patients before surgery, and after chemotherapy. The results indicated that ADA specific activity increased significantly (P

APA, Harvard, Vancouver, ISO, and other styles

7

Yildirim, Zeki, H. Canan Hasanoglu, Ömer Akyol, Münire Gokirmak, and Nurhan Köksal. "Serum adenosine deaminase activities in lung cancer and mesothelioma." Clinical Biochemistry 32, no. 4 (1999): 283–85. http://dx.doi.org/10.1016/s0009-9120(99)00013-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Wang, Lin, Luz M. Londono, Jessica Cowell, et al. "Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors." Cancer Research 81, no. 12 (2021): 3319–32. http://dx.doi.org/10.1158/0008-5472.can-21-0340.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

YOKOYAMA, M. M., and I. TSUBOI. "Adenosine Deaminase Isoenzymes and HIV/HTLV-1 Infections." JNCI Journal of the National Cancer Institute 80, no. 9 (1988): 698. http://dx.doi.org/10.1093/jnci/80.9.698.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Lee, Su-Chan, Lujain Alaali, HyukJean Kwon, Mohammed Rigi, and Charles G. Eberhart. "Abstract 1868: Targeting adenosine deaminase enhances anticancer effects of 3'-deoxyadenosine in uveal melanoma." Cancer Research 82, no. 12_Supplement (2022): 1868. http://dx.doi.org/10.1158/1538-7445.am2022-1868.

Full text

Abstract:

Abstract Uveal melanoma, which arises from melanocytes located in the uveal tract, is one of the most common primary intraocular cancers. GNAQ and GNA11 mutations, which are detected most of primary uveal melanoma, activate MAPK signaling pathway, increasing cancer cell proliferation, tumor progression and growth. BAP1 mutation is highly associated with liver metastasis and death. However, there are no good therapeutic compounds for uveal melanoma treatment in clinic. 3’-deoxyadenosine (cordycepin) is an adenosine analog which inhibits growth of several types of cancer. However, its anticancer

APA, Harvard, Vancouver, ISO, and other styles

11

O. Al-Gazally, Moaed. "Adenosine deaminase, AMP deaminase, 5`-Nucleotidase, Xanthine oxidase and Xanthine dehydrogenase Activities in Prostate Cancer Patients." AL-QADISIYAH MEDICAL JOURNAL 2, no. 3 (2017): 151–62. http://dx.doi.org/10.28922/qmj.2007.2.3.151-162.

Full text

Abstract:

The specific activities of some purine metabolism enzymes [Adenosine deaminase (ADA), AMP-deaminase, 5`-nucleotidase (5`- NT) and xanthine oxidase (the two forms: xanthine oxidase (XO) and xanthine dehydrogenase (XDH)], were measured in sera of control (n=45) and patients with prostate cancer (n=47).Sera ADA and AMPdeaminase specific activities in prostate cancer were significantly decreased (p<0.001) when compared with control group. By contrast there was significant increase (p<0.001) in 5`-NT specific activity observed in sera of prostate cancer. The activities of xanthine oxidase (XO

APA, Harvard, Vancouver, ISO, and other styles

12

Roberts, E. L., and O. T. Roberts. "Plasma adenosine deaminase isoform 2 in cancer patients undergoing chemotherapy." British Journal of Biomedical Science 69, no. 1 (2012): 11–13. http://dx.doi.org/10.1080/09674845.2012.11669915.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Yordanova, M., D. Gerova, and N. Kaloyanova. "Serum adenosine deaminase as breast and colorectal cancer progression biomarker." Clinica Chimica Acta 558 (May 2024): 118983. http://dx.doi.org/10.1016/j.cca.2024.118983.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kate, Joop Ten, Harry F. G. M. van de Ingh, P. Meera Khan, and Fré T. Bosman. "Adenosine deaminase complexing protein (ADCP) immunoreactivity in colorectal adenocarcinoma." International Journal of Cancer 37, no. 4 (1986): 479–85. http://dx.doi.org/10.1002/ijc.2910370402.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Nikkhoo, Bahram, Naseh Sigari, Bayazid Ghaderi, et al. "Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran." Journal of Medical Biochemistry 32, no. 2 (2013): 109–15. http://dx.doi.org/10.2478/jomb-2013-0011.

Full text

Abstract:

Summary Background: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, se

APA, Harvard, Vancouver, ISO, and other styles

16

Gentile, Chiara, Arianna Finizio, Guendalina Froechlich, et al. "Generation of a Retargeted Oncolytic Herpes Virus Encoding Adenosine Deaminase for Tumor Adenosine Clearance." International Journal of Molecular Sciences 22, no. 24 (2021): 13521. http://dx.doi.org/10.3390/ijms222413521.

Full text

Abstract:

Background: Oncolytic viruses are immunotherapeutic agents that can be engineered to encode payloads of interest within the tumor microenvironment to enhance therapeutic efficacy. Their therapeutic potential could be limited by many avenues for immune evasion exerted by the tumor. One such is mediated by adenosine, which induces pleiotropic immunosuppression by inhibiting antitumor immune populations as well as activating tolerogenic stimuli. Adenosine is produced starting from the highly immunostimulatory ATP, which is progressively hydrolyzed to ADP and adenosine by CD39 and CD73. Cancer cel

APA, Harvard, Vancouver, ISO, and other styles

17

Kutryb-Zajac, Barbara, Patrycja Koszalka, Paulina Mierzejewska, et al. "Adenosine deaminase inhibition suppresses progression of 4T1 murine breast cancer by adenosine receptor-dependent mechanisms." Journal of Cellular and Molecular Medicine 22, no. 12 (2018): 5939–54. http://dx.doi.org/10.1111/jcmm.13864.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Lal, Harbans, S. K. Munjal, Umesh Wig, and A. S. Saini. "Serum enzymes in head and neck cancer III." Journal of Laryngology & Otology 101, no. 10 (1987): 1062–65. http://dx.doi.org/10.1017/s0022215100103226.

Full text

Abstract:

AbstractSerum adenosine deaminase (ADA) levels were estimated in a group of 40 patients with head and neck cancer. The mean value was significantly higher in patients compared to controls. The increase was higher in cases of ulcerative growths than of proliferative growths, and activity was increased with advancement in the stage of the cancer. After radiotherapy, a gradual and significant decrease in serum ADA activity was observed.

APA, Harvard, Vancouver, ISO, and other styles

19

Ant, Ayça, Aslıhan Avcı, Metin Genç, Erdoğan İnal, Ümit Tunçel, and Ziya Şencan. "Avocado leaf extract activates Adenosine Deaminase (ADA) in Larynx cancer tissues." Acta Oncologica Turcica 51, no. 2 (2018): 199–204. http://dx.doi.org/10.5505/aot.2018.88319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Demir, Halit, Sıddık Keskin, Canan Demir, and Halis Gokyer. "The evaluation of diagnostic performance of some enzymes for diagnosis and detection of breast cancer by ROC curve." Medical Science and Discovery 3, no. 6 (2016): 250–54. https://doi.org/10.36472/msd.v3i6.147.

Full text

Abstract:

Objective: In this study, it was aimed to examine the performance of Arylesterase (ARE), Paraoxonase-1 (PON-1) and Adenosine deaminase (ADA) enzymes to identify cancer patients and their stages with ROC curve in serum samples taken from patients diagnosed as breast cancer in the Medical Oncology services at Yüzüncü Yıl University. Material and Methods: The 25 healthy controls and 25 breast cancer patients are included in this study. 8 patients are in stage-1, 9 patients are in stage-2 and 8 patients are in stage-3. Adenosine deaminase (ADA), Paraoxonase-1 (PON-1) and Arylesterase (ARE) activit

APA, Harvard, Vancouver, ISO, and other styles

21

Durak, Ilker, Recep Cetin, Orhan Canbolat, Deniz Cetin, Zühal Yurtarslani, and Abdülmutialip Ünal. "Adenosine deaminase, 5′-nucleotidase, guanase and cytidine deaminase activities in gastric tissues from patients with gastric cancer." Cancer Letters 84, no. 2 (1994): 199–202. http://dx.doi.org/10.1016/0304-3835(94)90376-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Sarkar, Omar Sadi, Howard Donninger, Lewis C. Chew, John Eaton, and Kavitha Yaddanapudi. "Enzymatic depletion of adenosine to overcome resistance to immune checkpoint inhibitors in non-small cell lung cancer." Journal of Immunology 210, no. 1_Supplement (2023): 230.14. http://dx.doi.org/10.4049/jimmunol.210.supp.230.14.

Full text

Abstract:

Abstract Despite the remarkable outcome of immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC), a large number of patients remain unresponsive to this therapy. A key factor of the unresponsiveness to ICIs is intrinsic therapeutic resistance where monocytic myeloid-derived suppressor cells (M-MDSCs) contribute significantly via suppressing CD8 +T cell mediated anti-tumor response. Our results showed that in tumor microenvironment (TME), tumor cells derived PGE 2; a prostaglandin that directly induces CD73 (an ecto-nucleotidase that converts AMP to immunosuppressive adenosi

APA, Harvard, Vancouver, ISO, and other styles

23

Horikami, Sandra M., and Sue A. Moyer. "Double-stranded RNA adenosine deaminase activity during measles virus infection." Virus Research 36, no. 1 (1995): 87–96. http://dx.doi.org/10.1016/0168-1702(94)00103-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Sharma, S., P. B. Desai, and R. B. Metgudmath. "Evaluation of Serum Adenosine Deaminase and Retinol in patients with Laryngeal Cancer." Indian Journal of Pharmaceutical and Biological Research 1, no. 04 (2013): 30–34. http://dx.doi.org/10.30750/ijpbr.1.4.6.

Full text

Abstract:

Laryngeal cancers account for 4% of all head and neck cancers in India. The disease process has better prognosis if it is diagnosed early. In view of this the objective of the study was to assess the reliability of serum enzyme marker adenosine deaminase and non-enzymatic antioxidant retinol in laryngeal cancer patients as supportive parameters for diagnostic purpose. Materials and methods:-25 clinically and histopathologically confirmed patients of laryngeal cancer in age group of 45-65 years were included in the study and 25 healthy subjects with in the same age group served as controls. Res

APA, Harvard, Vancouver, ISO, and other styles

25

Dasmahapatra, Kumar S., Helene Z. Hill, Amita Dasmahapatra, and Sara Suarez. "Evaluation of adenosine deaminase activity in patients with head and neck cancer." Journal of Surgical Research 40, no. 4 (1986): 368–73. http://dx.doi.org/10.1016/0022-4804(86)90201-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Narla, Anupama, Bertil Glader, and Carolyn Wong. "Understanding the Role of Erythrocyte Adenosine Deaminase in the Ribosomopathies." Blood 124, no. 21 (2014): 5152. http://dx.doi.org/10.1182/blood.v124.21.5152.5152.

Full text

Abstract:

Abstract Diamond Blackfan anemia (DBA) is congenital bone marrow failure syndrome characterized by red cell aplasia and a predisposition to cancer. It was the first disease linked to ribosomal dysfunction with 70% of patients having haploinsufficiency of a ribosomal protein (RP) gene with RPS19 being the most frequently mutated. The 5q- syndrome is a subtype of myelodysplastic syndrome (MDS) also characterized by a severe anemia that is caused by heterozygous loss of RPS14 on chromosome 5q. These patients also have a predisposition to cancer. The reciprocal relationship between these two disea

APA, Harvard, Vancouver, ISO, and other styles

27

Schwenzer, Hagen P., Stefan N. Symeonides, Elizabeth Ruth Plummer, Gareth P. Bond, and Sarah Patricia Blagden. "A first-in-human study of, NUC-7738, a 3'dA phosphoramidate, in patients with advanced solid tumors or lymphoma (NuTide 701)." Journal of Clinical Oncology 37, no. 15_suppl (2019): TPS3147. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.tps3147.

Full text

Abstract:

TPS3147 Background: Nucleoside analogs form the backbone therapy for both hematological and solid malignancies. However, their clinical effectiveness is severely limited by key cellular resistance mechanisms linked to increased breakdown, impaired activation and transport. NUC-7738 is a phosphoramidate transformation of cordycepin (3’-deoxyadenosine; 3’-dA), a derivative of adenosine that was first isolated from Cordyceps sinensis. The cytotoxic effect of 3’-dA is largely attributed to intracellular generation of the triphosphate metabolite, 3’-dATP, terminating DNA and RNA synthesis. Although

APA, Harvard, Vancouver, ISO, and other styles

28

Canbolat, Orhan, Ilker Durak, Recep Çetin, Mustafa Kavutcu, Salim Demirci, and Serdar Öztürk. "Activities of adenosine deaminase, 5′-nucleotidase, guanase, and cytidine deaminase enzymes in cancerous and non-cancerous human breast tissues." Breast Cancer Research and Treatment 37, no. 2 (1996): 189–93. http://dx.doi.org/10.1007/bf01806500.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Hu, Xueda, Jingyi Chen, Xiaoshun Shi, et al. "RNA editing of AZIN1 induces the malignant progression of non-small-cell lung cancers." Tumor Biology 39, no. 8 (2017): 101042831770000. http://dx.doi.org/10.1177/1010428317700001.

Full text

Abstract:

RNA editing is a widespread post-transcriptional mechanism that confers specific and reproducible nucleotide changes in selected RNA transcripts and plays a critical role in many human cancers. However, little is known about how RNA editing operates in non-small-cell lung cancers. Here, we measured the sequence and expression level of genes of antizyme inhibitor 1 and adenosine deaminase acting on RNA family in 30 non-small-cell lung cancer patient samples and 13 cell lines and revealed RNA editing S367G in antizyme inhibitor 1 is a high-frequent molecular events. We determined overexpression

APA, Harvard, Vancouver, ISO, and other styles

30

GÖKYER, Halis, Halit DEMIR, Canan DEMIR, and Erkan DOĞAN. "Investigation of Adenosine Deaminase, Aryl Esterase And Paraoxanaz-1 Serum Activities in Patients with Breast Cancer." International Journal of Medicine and Occupational Health and Safety Sciences 1, no. 2 (2023): 90–100. https://doi.org/10.5281/zenodo.10431468.

Full text

Abstract:

Aim: The purpose of the that study was to compare enzyme activities such as arylesterase (ARE), paraoxonase-1 (PON1), and adenosine deaminase (ADA) in patients with breast cancer. Materials and Methods:<strong> </strong>Adenosine deaminase (ADA), paraoxanase (PON-1) and arilesterase (ARE) activities were determined by spectrophotometer in the serums dissolved by centrifugation of blood samples from the patients with breast cancer. Results:<strong> </strong>The PON-1 activity of patient group (at phase-1, phase-2 and phase-3) was found significantly more lower than the healthy control group in

APA, Harvard, Vancouver, ISO, and other styles

31

Ali, Zahraa Mohammed. "Study of serum adenosine deaminase -2 (ADA-2) activity in rheumatoid arthritis." BASRA JOURNAL OF SCIENCE 39, no. 1 (2021): 119–34. http://dx.doi.org/10.29072/basjs.202118.

Full text

Abstract:

Prevent joint pain early detection of Rheumatoid arthritis (R.A.) is required. Adenosine deaminase-2 (ADA-2) plays a vital role in R.A. Our study aimed to assay the level of serum ADA-2 activity for R.A. patients. Purification of ADA-2 from the serum of patients and study cytotoxicity of purified ADA-2 on breast cancer (MCF-7) cell line and standard cell line (WRL-68). Activity levels of t-ADA, ADA-1, and ADA-2 were estimated. Also, isolated and purified ADA-2 from serum R.A, and finally, the cytotoxic activity of purified ADA-2 on MFC-7 and WRL -68 cells for 24h was examined using MTT assay.

APA, Harvard, Vancouver, ISO, and other styles

32

Ghali, Kareem Hamed. "Measurement of Activities of Adenosine Deaminase and Superoxide Dismutase in Bladder Cancer Patients." Journal of Wasit for Science and Medicine 2, no. 1 (2022): 132–43. http://dx.doi.org/10.31185/jwsm.38.

Full text

Abstract:

The biochemical study investigated the specific activity of two enzymes; adenosine deaminase (ADA) and superoxide dismutase (SOD) in the sera of eighty three blader cancer (BC) patients and twenty controls. A significant reduced specific activity of ADA was observed in the patients (0.136 U/gm vs. 0.206 U/gm ), while SOD contrasted the picture, and instead, a significant elevation of the activity was observed (11.430 U/ml vs. 8 585 U/ml )., especially in the advanced stages of disease

APA, Harvard, Vancouver, ISO, and other styles

33

Faisal, AlRubaye, and Morad Taha. "Serum adenosine deaminase activity in Iraqi patients with breast cancer on tamoxifen therapy." Gaziantep Medical Journal 18, no. 3 (2012): 139. http://dx.doi.org/10.5455/gmj-30-2012-96.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Asadi, A., S. M. Atyab, and S. Sadeghi. "Evaluation of serum adenosine deaminase and its isoenzymes in patients with ovarian cancer." Ukrainian Biochemical Journal 90, no. 4 (2018): 111–14. http://dx.doi.org/10.15407/ubj90.04.111.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pirinççi, N., I. Geçit, M. Güneş, et al. "Serum adenosine deaminase, catalase and carbonic anhydrase activities in patients with bladder cancer." Clinics 67, no. 12 (2012): 1443–46. http://dx.doi.org/10.6061/clinics/2012(12)15.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

SAMEE, A., R. SCREEN, E. MOSS, S. POUNTAIN, M. DEAKIN, and P. HOBAN. "Preliminary analysis of double-stranded RNA Adenosine Deaminase enzyme (dsRAD, ADAR1) in cancer." European Journal of Surgical Oncology (EJSO) 33, no. 9 (2007): 1104–5. http://dx.doi.org/10.1016/j.ejso.2007.07.030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

HUANG, JUN, YUJIAO HE, MINGNA CHEN, et al. "Adenosine deaminase and adenosine kinase expression in human glioma and their correlation with glioma-associated epilepsy." Molecular Medicine Reports 12, no. 5 (2015): 6509–16. http://dx.doi.org/10.3892/mmr.2015.4285.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Thuy-Boun, Alexander S., Justin M. Thomas, Herra L. Grajo, et al. "Asymmetric dimerization of adenosine deaminase acting on RNA facilitates substrate recognition." Nucleic Acids Research 48, no. 14 (2020): 7958–72. http://dx.doi.org/10.1093/nar/gkaa532.

Full text

Abstract:

Abstract Adenosine deaminases acting on RNA (ADARs) are enzymes that convert adenosine to inosine in duplex RNA, a modification that exhibits a multitude of effects on RNA structure and function. Recent studies have identified ADAR1 as a potential cancer therapeutic target. ADARs are also important in the development of directed RNA editing therapeutics. A comprehensive understanding of the molecular mechanism of the ADAR reaction will advance efforts to develop ADAR inhibitors and new tools for directed RNA editing. Here we report the X-ray crystal structure of a fragment of human ADAR2 compr

APA, Harvard, Vancouver, ISO, and other styles

39

Kutryb-Zajac, Barbara, Gabriela Harasim, Agata Jedrzejewska, et al. "Macrophage-Derived Adenosine Deaminase 2 Correlates with M2 Macrophage Phenotype in Triple Negative Breast Cancer." International Journal of Molecular Sciences 22, no. 7 (2021): 3764. http://dx.doi.org/10.3390/ijms22073764.

Full text

Abstract:

Several lines of evidence suggest that altered adenosine deaminase (ADA) activity, especially its ADA2 iso-enzyme, is associated with malignant breast cancer (BC) development. Triple-negative breast cancer (TNBC) is currently the most challenging BC subtype due to its metastatic potential and recurrence. Herein, we analyzed the sources of ADA iso-enzymes in TNBC by investigating the effects of cell-to-cell interactions between TNBC cells, macrophages, lymphocytes, and endothelial cells. We also examined the potential relationship between ADA activity and cancer progression in TNBC patients. In

APA, Harvard, Vancouver, ISO, and other styles

40

Monroy-Mora, Alberto, María de Lourdes Mora-García, Katia Alheli Monroy Mora, et al. "Inhibition of adenosine deaminase activity reverses resistance to the cytotoxic effect of high adenosine levels in cervical cancer cells." Cytokine 158 (October 2022): 155977. http://dx.doi.org/10.1016/j.cyto.2022.155977.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Kojima, Osamu, Takashi Majima, Yasuo Uehara, et al. "Alteration of adenosine deaminase levels in peripheral blood lymphocytes of patients with gastric cancer." Japanese Journal of Surgery 15, no. 2 (1985): 130–33. http://dx.doi.org/10.1007/bf02469742.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Salameh, Ahmad, Alessandro K. Lee, Marina Cardó-Vila, et al. "PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3." Proceedings of the National Academy of Sciences 112, no. 27 (2015): 8403–8. http://dx.doi.org/10.1073/pnas.1507882112.

Full text

Abstract:

Prostate cancer antigen 3 (PCA3) is the most specific prostate cancer biomarker but its function remains unknown. Here we identify PRUNE2, a target protein-coding gene variant, which harbors the PCA3 locus, thereby classifying PCA3 as an antisense intronic long noncoding (lnc)RNA. We show that PCA3 controls PRUNE2 levels via a unique regulatory mechanism involving formation of a PRUNE2/PCA3 double-stranded RNA that undergoes adenosine deaminase acting on RNA (ADAR)-dependent adenosine-to-inosine RNA editing. PRUNE2 expression or silencing in prostate cancer cells decreased and increased cell p

APA, Harvard, Vancouver, ISO, and other styles

43

Lee, Su-Chan, Lujain Alaali, HyukJean Kwon, Mohammed Rigi, and Charles G. Eberhart. "Cordycepin (3′-Deoxyadenosine) Suppresses Heat Shock Protein 90 Function and Targets Tumor Growth in an Adenosine Deaminase-Dependent Manner." Cancers 14, no. 13 (2022): 3122. http://dx.doi.org/10.3390/cancers14133122.

Full text

Abstract:

Alterations in metabolism and energy production are increasingly being recognized as important drivers of neoplasia, raising the possibility that metabolic analogs could disrupt oncogenic pathways. 3′-deoxyadenosine, also known as cordycepin, is an adenosine analog that inhibits the growth of several types of cancer. However, the effects of cordycepin have only been examined in a limited number of tumor types, and its mechanism of action is poorly understood. We found that cordycepin slows the growth and promotes apoptosis in uveal melanoma, as well as a range of other hard-to-treat malignanci

APA, Harvard, Vancouver, ISO, and other styles

44

Silvestris, Domenico Alessandro, Chiara Scopa, Sara Hanchi, Franco Locatelli, and Angela Gallo. "De Novo A-to-I RNA Editing Discovery in lncRNA." Cancers 12, no. 10 (2020): 2959. http://dx.doi.org/10.3390/cancers12102959.

Full text

Abstract:

Background: Adenosine to inosine (A-to-I) RNA editing is the most frequent editing event in humans. It converts adenosine to inosine in double-stranded RNA regions (in coding and non-coding RNAs) through the action of the adenosine deaminase acting on RNA (ADAR) enzymes. Long non-coding RNAs, particularly abundant in the brain, account for a large fraction of the human transcriptome, and their important regulatory role is becoming progressively evident in both normal and transformed cells. Results: Herein, we present a bioinformatic analysis to generate a comprehensive inosinome picture in lon

APA, Harvard, Vancouver, ISO, and other styles

45

Chinsky, Jeffrey M., V. Ramamurthy, William C. Fanslow, et al. "Developmental expression of adenosine deaminase in the upper alimentary tract of mice." Differentiation 42, no. 3 (1990): 172–83. http://dx.doi.org/10.1111/j.1432-0436.1990.tb00759.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Rieth, A., and A. Ludäscher. "Pentostatin (2′-Deoxycoformycin, Nipent^®): A Structural Analogue of the Purine Adenosine Acting as Potent Adenosine Deaminase Inhibitor." Oncology Research and Treatment 18, no. 4 (1995): 302–9. http://dx.doi.org/10.1159/000218609.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

., A. Avci, M. Kacmaz ., M. Kavutcu ., E. Gocmen ., and I. Durak . "Effects of an Antioxidant Extract on Adenosine Deaminase Activities in Cancerous Human Liver Tissues." International Journal of Cancer Research 1, no. 1 (2004): 53–56. http://dx.doi.org/10.3923/ijcr.2005.53.56.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Pan, Zhian. "ADAR1 and ZBP1 in Breast Cancer: Pathological Mechanism and Therapeutics." International Journal of Biology and Life Sciences 7, no. 2 (2024): 11–16. http://dx.doi.org/10.54097/fr2bb227.

Full text

Abstract:

Breast cancer is a heterogeneous disease in which a variety of genetic and environmental factors are involved. Among them, adenosine deaminase acting on RNA 1 (ADAR1) and Z-DNA binding protein 1 (ZBP1) are the factors that have opposite functions in the process of regulating cell viability as well as inflammatory and immunity. Recently, the two factors have been proved to act as a key player in caspase-8-dependent PANotosis and IFN-γ-dependent immunoregulation in the development of most types of cancers. In this review, we discuss the basic functions of ADAR1 and ZBP1 as well as the interactio

APA, Harvard, Vancouver, ISO, and other styles

49

Di Marco, Pietro, Daniela Tinnirello, Mario Tambone-Reyes, Laura Tedesco, Salvatore Luna, and Pietro Citarella. "Biologic Relevance of Elevated Red Cell Adenosine Deaminase Activity in Myelodysplastic Syndromes and Paroxysmal Nocturnal Hemoglobinuria." Tumori Journal 78, no. 6 (1992): 370–73. http://dx.doi.org/10.1177/030089169207800604.

Full text

Abstract:

Red cell adenosine deaminase (ADA-RBC) activity in patients with myelodysplastic syndromes and paroxysmal nocturnal hemoglobinuria is significantly increased compared to that observed in normal controls. ADA-RBC activity is not related to fetal hemoglobin concentration, but it is significantly correlated with hemoglobin concentration at diagnosis and with the degree of morphologic dysplasia in the erythroid lineage. The results of our study suggest that the observed enzymatic abnormality may constitute a non-specific manifestation of the stem cell alteration that determines these disorders.

APA, Harvard, Vancouver, ISO, and other styles

50

Honma, Yoshio. "A Novel Therapeutic Strategy Against Monocytic Leukemia with Deoxyadenosine Analogs and Adenosine Deaminase Inhibitors." Leukemia & Lymphoma 42, no. 5 (2001): 953–62. http://dx.doi.org/10.3109/10428190109097714.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!